Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T79798 | ||||
Target Name | MAP kinase p38 | ||||
Target Type | Clinical Trial |
||||
Drug Potency against Target | BIRB 796 | Drug Info | IC50 = 0.1 nM | [552495] | |
VX-745 | Drug Info | IC50 = 0.8 nM | [552773] | ||
ML-3403 | Drug Info | IC50 = 990 nM | [526668] | ||
ML-3163 | Drug Info | IC50 = 880 nM | [526355] | ||
RWJ-68354 | Drug Info | IC50 = 7 nM | [526530] | ||
ML-3375 | Drug Info | IC50 = 1200 nM | [526668] | ||
Talmapimod | Drug Info | IC50 = 9 nM | [552972] | ||
VK-19911 | Drug Info | IC50 = 71 nM | [526904] | ||
Action against Disease Model | VX-745 | VX-745 induces modest growth inhibition of MM.1S, RPMI8226, and U266 cell lines in a dose-dependent fashion, with inhibitory concentration of 50% (IC50) of 10 M as assessed by MTT assay. | [552312] | Drug Info | |
The Effect of Target Knockout, Knockdown or Genetic Variations | Mice lacking p38delta gene exhibited a marked resistance to development of 7,12-dimethylbenz(a)anthracene/12-O-tetra-decanoylphorbol-13-acetate-induced skin papillomas,with increased latency and greatly reduced incidence, multiplicity, and size of t uMors compared with wild-type mice. Our data suggest that the underlying mechanism for reduced susceptibility to skin carcinogenesis in p38delta-null mice involves a defect in proliferative response associated with aberrant signaling through the two major transformation-promoting pathways:extracellular signal-regulated kinase1/2-activator protein and signal transducer and activator of transcription.These findings strongly suggest an in vivo role for p38D in promoting cell proliferation and t uMor development in epidermisand may have therapeutic implication for skin cancer. | [552495] | |||
References | |||||
Ref 552495 | A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005 Mar;23(3):329-36. Epub 2005 Feb 13. | ||||
Ref 552773 | A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358. | ||||
Ref 552312 | Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15;101(2):703-5. Epub 2002 Sep 5. | ||||
Ref 526668 | J Med Chem. 2003 Jul 17;46(15):3230-44.Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. | ||||
Ref 526355 | J Med Chem. 2002 Jun 20;45(13):2733-40.From imidazoles to pyrimidines: new inhibitors of cytokine release. | ||||
Ref 526530 | Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.Imidazopyrimidines, potent inhibitors of p38 MAP kinase. | ||||
Ref 526668 | J Med Chem. 2003 Jul 17;46(15):3230-44.Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. | ||||
Ref 552972 | Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem. 2009;9(7):655-76. | ||||
Ref 526904 | J Med Chem. 2003 Dec 18;46(26):5651-62.Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.